Tags

Type your tag names separated by a space and hit enter

Cutaneous ulcers associated with hydroxyurea therapy in myeloproliferative disorders.
Leuk Lymphoma. 1999 Sep; 35(1-2):109-18.LL

Abstract

Hydroxyurea (HU) is an established chemotherapeutic agent in the treatment of myeloproliferative disorders (MPD) including chronic myelogenous leukemia (CML), polycythemia vera and essential thrombocythemia (ET). It is well tolerated, has minimal toxicities, and produces hematological response in most patients treated. Side effects of hydroxyurea are few and include myelosuppression, oral ulcers and skin rashes. Cutaneous toxicity is rare. This study aims to describe the occurrence of cutaneous ulcerations attributed to HU therapy in patients with MPD, and familiarize the oncology community with this unusual but disturbing toxicity of HU. Five patients with MPD receiving HU therapy at doses of 0.5 to 4 g/day who developed skin ulceration were reviewed (median age was 53 years). Three patients had Philadelphia positive CML, and two had ET. Cutaneous ulcers developed after a long period of HU therapy (median 36 months, range 7 to 96 months). The time after discontinuation of HU to the healing of the ulcers was 1 to 4 months. Ulcers developed mainly in the lower extremities particularly adjacent to the malleoli, indicating a possible relation to trauma. In conclusion, cutaneous ulceration represents a poorly recognized and rare HU-related side effect. Discontinuation of HU usually leads to slow resolution of the ulcers over several months. The etiology of this rare side effect remains poorly understood.

Authors+Show Affiliations

Department of Leukemia, M.D. Anderson Cancer Center, Houston, Texas 77030, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Case Reports
Journal Article

Language

eng

PubMed ID

10512168

Citation

Ravandi-Kashani, F, et al. "Cutaneous Ulcers Associated With Hydroxyurea Therapy in Myeloproliferative Disorders." Leukemia & Lymphoma, vol. 35, no. 1-2, 1999, pp. 109-18.
Ravandi-Kashani F, Cortes J, Cohen P, et al. Cutaneous ulcers associated with hydroxyurea therapy in myeloproliferative disorders. Leuk Lymphoma. 1999;35(1-2):109-18.
Ravandi-Kashani, F., Cortes, J., Cohen, P., Talpaz, M., O'Brien, S., Markowitz, A., & Kantarjian, H. (1999). Cutaneous ulcers associated with hydroxyurea therapy in myeloproliferative disorders. Leukemia & Lymphoma, 35(1-2), 109-18.
Ravandi-Kashani F, et al. Cutaneous Ulcers Associated With Hydroxyurea Therapy in Myeloproliferative Disorders. Leuk Lymphoma. 1999;35(1-2):109-18. PubMed PMID: 10512168.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cutaneous ulcers associated with hydroxyurea therapy in myeloproliferative disorders. AU - Ravandi-Kashani,F, AU - Cortes,J, AU - Cohen,P, AU - Talpaz,M, AU - O'Brien,S, AU - Markowitz,A, AU - Kantarjian,H, PY - 1999/10/8/pubmed PY - 2000/8/12/medline PY - 1999/10/8/entrez SP - 109 EP - 18 JF - Leukemia & lymphoma JO - Leuk Lymphoma VL - 35 IS - 1-2 N2 - Hydroxyurea (HU) is an established chemotherapeutic agent in the treatment of myeloproliferative disorders (MPD) including chronic myelogenous leukemia (CML), polycythemia vera and essential thrombocythemia (ET). It is well tolerated, has minimal toxicities, and produces hematological response in most patients treated. Side effects of hydroxyurea are few and include myelosuppression, oral ulcers and skin rashes. Cutaneous toxicity is rare. This study aims to describe the occurrence of cutaneous ulcerations attributed to HU therapy in patients with MPD, and familiarize the oncology community with this unusual but disturbing toxicity of HU. Five patients with MPD receiving HU therapy at doses of 0.5 to 4 g/day who developed skin ulceration were reviewed (median age was 53 years). Three patients had Philadelphia positive CML, and two had ET. Cutaneous ulcers developed after a long period of HU therapy (median 36 months, range 7 to 96 months). The time after discontinuation of HU to the healing of the ulcers was 1 to 4 months. Ulcers developed mainly in the lower extremities particularly adjacent to the malleoli, indicating a possible relation to trauma. In conclusion, cutaneous ulceration represents a poorly recognized and rare HU-related side effect. Discontinuation of HU usually leads to slow resolution of the ulcers over several months. The etiology of this rare side effect remains poorly understood. SN - 1042-8194 UR - https://www.unboundmedicine.com/medline/citation/10512168/Cutaneous_ulcers_associated_with_hydroxyurea_therapy_in_myeloproliferative_disorders_ L2 - https://www.tandfonline.com/doi/full/10.3109/10428199909145710 DB - PRIME DP - Unbound Medicine ER -